Arecor announces oral presentation at Attd 2022

Arecor announces oral presentation at attd 2022 of phase 1 clinical trial of at278 ultra-concentrated ultra-rapid acting, insulin for diabetes.

Arecor Therapeutics plc, a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that its abstract titled AT278 (U500) – PK/PD and safety of rapid-acting concentrated insulin aspart”, has been selected for oral presentation at the upcoming 15th International Conference on Advanced Technologies and Treatments ForDiabetes (ATTD) meeting which will be held from 27-30 April 2022 in Barcelona.

The presentation will take place at 17:20 on Thursday 28 April during the Oral Presentations Session 2 in Hall 118 of the Conference Centre.

 

Oral Presentation:         AT278 (U500) – PK/PD and safety of rapid-acting concentrated insulin aspart

Presenting Author:         Dr Eva Svehlikova

Session:                            Oral Presentations Session 2

Date and Time:               Thursday, 28 April 2022, at 17:20 Central European Time

 

AT278, is an ultra-concentrated (500U/mL) novel formulation of insulin, that has been designed to significantly accelerate insulin absorption post injection to enable more effective and convenient management of blood glucose levels in people with high daily insulin requirements.

In addition, a poster titled ‘Adjusting insulin therapy to faster insulin analogs leads to improved glucose control: An in-silico analysis’ will be presented at ATTD by Dr Jenny Diaz from the University of Virginia.  The in-silico analysis suggests that the faster PK/PD profile of Arecor’s AT247, an investigational ultra-rapid acting (100U/mL) insulin formulation, has the potential to significantly improve glucose control in closed loop systems.

Sarah Howell, Chief Executive Officer at Arecor, said: “We are very excited to be able to share these ground-breaking data for AT278 and AT247 at the ATTD conference. AT278 has the potential to be the first and perhaps only concentrated (500U/mL) rapid acting insulin available to patients, having clearly demonstrated faster insulin absorption with an accelerated pharmacokinetic (PK) and pharmacodynamic (PD) profile compared to gold-standard insulin NovoRapid® despite a 5-fold increase in concentration, in this first Phase I clinical study. In addition, in partnership with the University of Virginia, we are excited to be able to share results from their in-silico analysis demonstrating the potential for AT247 to enable a fully closed loop artificial pancreas, which would be a life-changing treatment option for people living with Type 1 diabetes.”

 

 

Looking for something specific?